News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Mineralys Therapeutics insider David Rodman has filed a Form 144, indicating his intention to sell up to 14,056 shares of common stock through Merrill Lynch on or after August 13, 2026. The aggregate market value of the planned sale is $372,187.00. These shares originate …
Mineralys Therapeutics, Inc. announced an inducement stock option award of 135,000 shares and a restricted stock unit award of 102,400 shares to Dr. Terry Ferguson, their new Chief Medical Officer. These awards, granted on August 10, 2026, are part of the company's 2025 Employment …
Mineralys Therapeutics (Nasdaq: MLYS) announced that its independent directors granted inducement equity awards to newly appointed Chief Medical Officer Dr. Terry Ferguson on August 10, 2026. These awards include a stock option for 135,000 shares and a restricted stock unit (RSU) award for 102,400 …
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, exercised 2,170 stock options for common stock at $16.00 per share and subsequently sold those 2,170 shares at $27.09 per share on August 10, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted …
Mineralys Therapeutics insider David Malcom Rodman sold 2,170 shares of the company's stock for $58,785.30, reducing his holdings by 4.05%. This transaction, conducted under a pre-arranged Rule 10b5-1 plan, follows several other sales by Rodman in recent months. The company recently reported a significant …
Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold 2,170 shares for $58,785 and exercised stock options for an equal number of shares. These transactions were part of a Rule 10b5-1 trading plan. The company's shares show a significant annual return despite a year-to-date …
Mineralys Therapeutics reported a wider second-quarter loss due to a $200 million payment for an amended agreement with Tanabe Pharma, but is progressing with commercial-launch preparations for lorundrostat ahead of its December PDUFA date. The company highlighted positive clinical data for lorundrostat in various …
The average 12-month price target for Mineralys Therapeutics, Inc. (MLYS) stock has been slightly reduced from $49 to $48.5 by 8 analysts, with forecasts ranging from $30 to $56 per share. This new target suggests a potential upside of approximately 77% from the August …
Mineralys Therapeutics reported a wider Q2 2026 net loss of US$241.07 million, alongside confirming a December 22, 2026 PDUFA target date for its lead asset, lorundrostat, and repurchasing a royalty obligation. This update highlights management's dual focus on regulatory progress and enhancing long-term economics, …
Mineralys Therapeutics is preparing to announce its second-quarter earnings, with analysts anticipating a widening of losses as the company advances its hypertension drug, lorundrostat, towards a potential FDA decision in December 2026. Despite the projected increase in losses, reflecting ongoing cash burn for commercialization, …
Mineralys Therapeutics (NASDAQ:MLYS) reported a wider-than-expected second-quarter loss of $2.85 per share, missing analyst estimates of $2.63 per share. This loss was primarily due to a $200 million upfront payment to Tanabe and increased research and development, along with general and administrative expenses. Despite …
Mineralys Therapeutics reported a widened net loss of $280.4 million for the first half of 2026, primarily due to a $200 million upfront R&D charge for a perpetual, royalty-free license for its hypertension candidate, lorundrostat. Despite the loss, the company strengthened its financial position …
Mineralys Therapeutics announced its second quarter 2026 financial results, highlighting progress in its clinical programs. The company provided an update on its corporate activities, focusing on key developments and future outlook. This release details the financial performance and strategic advancements made during the quarter.
Mineralys Therapeutics reported its Q2 2026 financial results, including a $241 million net loss, and provided a corporate update on its aldosterone synthase inhibitor, lorundrostat. The FDA has set a PDUFA target date of December 22, 2026, for lorundrostat, and Mineralys is actively preparing …
Mineralys Therapeutics Inc. (MLYS) shows a positive near-term sentiment with a potential shift, indicating broader weak alignment within a mid-channel oscillation pattern. AI models suggest specific trading strategies for different risk profiles, highlighting a notable 109.0:1 risk-reward setup targeting a 29.4% gain versus 0.3% …
Mineralys Therapeutics, Inc. reported a significant increase in its net loss for Q2 2026, reaching $(241.1)M, or $(2.85) per diluted share, compared to $(43.3)M in Q2 2025, with no product revenue generated to date. The company highlighted progress in its pipeline, including the NDA …
MINERALYS THERAPEUTICS ($MLYS) reported its Q2 2026 earnings, missing analyst estimates with -$2.85 per share against an expected -$0.55, and revenue matching expectations at $0. Following the announcement, the stock price declined by 4.32%. The article also details significant insider trading activity, with 39 …
Mineralys Therapeutics announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is preparing for the commercial launch of lorundrostat, pending FDA approval by the PDUFA target date of December 22, 2026, and has appointed …
David Rodman has filed a Rule 144 notice to sell 2,170 shares of Mineralys Therapeutics, Inc. common stock through Merrill Lynch on August 10, 2026. This planned sale is connected to the exercise of employee stock options via a cashless exercise. The filing also …
FMR LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 5.1% in Mineralys Therapeutics, Inc. (MLYS), which accounts for 4,461,689.46 shares of common stock. The filing specifies that FMR LLC holds sole voting power over 4,461,164.00 shares and sole dispositive power …
Mineralys Therapeutics (MLYS) is set to report its Q2 2026 earnings on August 11, 2026, with its stock currently seen as 47.9% undervalued by analysts, suggesting a fair value of $50.88 compared to its recent close of $26.50. This valuation hinges on the potential …
Mineralys Therapeutics (Nasdaq: MLYS) announced it will report its second-quarter 2026 financial results after market close on Tuesday, August 11, 2026. The company will host a conference call and live webcast for investors and analysts at 4:30 p.m. ET on the same day to …
Mineralys Therapeutics, Inc. announced it will report its financial results for the second quarter ended June 30, 2026, after the financial markets close on Tuesday, August 11, 2026. The company will host a conference call on the same day at 4:30 p.m. ET to …
Renaissance Technologies LLC increased its stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 18.8% in the first quarter, acquiring an additional 60,700 shares to reach a total of 382,800 shares valued at approximately $10.37 million. Despite significant insider selling totaling over $6.2 million, analyst sentiment …
Certain Restricted Stock Units of Mineralys Therapeutics, Inc. are under a lock-up agreement that will end on August 3, 2026. These units were locked up for 61 days, starting from June 3, 2026. This announcement highlights the conclusion of a restricted period for these …
Mineralys Therapeutics Inc. (NASDAQ: MLYS) is showing weak sentiment across all time horizons, supporting a short bias. Quantitative Research Desk analysis indicates a mid-channel oscillation pattern and an exceptional 107.1:1 risk-reward short setup. The article provides detailed institutional trading strategies, including position trading, momentum …
Search by ticker symbol or company name and select a result to open its chart.